Characterization and Preclinical Perspectives of Organic Small Molecule Drug Metabolites in Drug-drug Interactions

Author(s): Liqian Gao, Jun Chen, Yi Hu, Hongyan Sun, Yong Siang Ong, Jingxin Zhang, Zhifang Chai, Su Seong Lee.

Journal Name: Current Organic Chemistry

Volume 20 , Issue 17 , 2016

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

The potential of metabolites to contribute to drug-drug interactions (DDIs) has not been well defined so far. However, metabolites of parent drug compounds can contribute to both side effects and DDIs. To address this unmet challenge, we introduce recent advances as well as our perspectives of the metabolites in DDIs in this review. Firstly, we review several typical examples of organic small molecule drug metabolites asmajor contributors to DDIs in clinic. Since some of the metabolites are so important in the contributions to DDIs, we then further review how to identify active metabolites in vivo and when such metabolites should trigger DDI assessment. Lastly, we review in vivo animal models, especially humanized/chimeric mice, in improving the quality of preclinical DDI assessments.

Keywords: Bupropion, drug-drug interactions (DDIs), gemfibrozil, metabolites, pharmacodynamics, pharmacokinetics.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 20
ISSUE: 17
Year: 2016
Page: [1827 - 1834]
Pages: 8
DOI: 10.2174/1385272820666151102212542
Price: $58

Article Metrics

PDF: 19
HTML: 1
EPUB: 1
PRC: 1